A Phase 2, open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)
Westin, J. Burke, J. M. Chapman, A. E. Kilavuz, T. Xu, C. Schmuely, Y. Stanford, B. L. Beedle, E.
Westin, J.
Burke, J. M.
Chapman, A. E.
Kilavuz, T.
Xu, C.
Schmuely, Y.
Stanford, B. L.
Beedle, E.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Westin J, Burke JM, Chapman AE, Kilavuz T, Xu C, Schmuely Y, et al. A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9). Blood. 2022 Nov;140:6638-9. PubMed PMID: WOS:000893223206291.